Abstract 444P
Background
Cancer care in French Polynesia has been deprioritized during severe acute respiratory syndrome coronavirus 2 (SARS CoV2) pandemic due to the urgent necessity to reorganize health care systems to fight this crisis and patients (pts) were more reluctant to visit medical doctors, fearful about exposure to the virus or not wanting to disturb a saturated health system.
Methods
We aimed to assess the incidence of cancer diagnosis and cancer care during the Covid-19 period compared to the same period in 2019 (before covid) and in 2021 (after covid). We retrospectively collected data from January 2019 to Sept 2021 regarding pts visits, treatments (ttt) administrations in oncology and radiotherapy outpatient wards, at the Taaone university hospital center of French Polynesia.
Results
Regarding the newly diagnosed pts, we observed a decreased of 13.6% on oncology visits from January to Sept 2020 compared to the same period in 2019 and an increase of oncology visits after the first wave with +14.2%, from January to Sept 2021 compared to 2020. We did not observe any major impact of the crisis on ttt administrations in oncology outpatients. There was a +1.3% of activity from January to Sept 2020 compared to 2019 and a +1.5% from January to Sept 2021 compare to 2020. Regarding the radiotherapy activity, the newly diagnosed pts visits increased of +2.5% from January to Sept 2020 compared to the same period in 2019 and +21% from January to Sept 2021 compared to the same period in 2020. The ttts in radiotherapy outpatient wards decreased of -11% in 2020 (from January to Sept 2020 compared to 2019) and increased of +11% in 2021.
Conclusions
The covid 19 crisis had an impact in French Polynesia on the oncology and radiotherapy visit of the newly diagnosed patients, with more patients diagnosed after covid; while ttt administrations in oncology and radiotherapy stayed stable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06